Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

The crowd settles in for Xconomy's Boston Life Sciences 2032 forum.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Deborah Dunsire, CEO of Millennium: The Takeda Oncology Company, gives the opening keynote.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

The audience gets some formidable questions ready for the speakers.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

All-star cast on the panel (left to right): John Mendlein, Michael Bonney, Noubar Afeyan, Dennis Ausiello.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Standing-room-only crowd takes in the discussion of Boston biotech's past, present, and future.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

John Mendlein, CEO and executive chairman of aTyr Pharma and vice chairman of Fate Therapeutics, was the maestro moderator.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Michael Bonney, CEO of Cubist Pharmaceuticals, discussed how the landscape has changed since he joined Biogen 17 years ago.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Noubar Afeyan, managing partner and CEO of Flagship Ventures, talked about how startups happen.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Dennis Ausiello, chief of medicine at Mass. General Hospital, made points about intellectual capital and big pharma.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston LIfe Sciences 2032

Xconomy Xchange: Boston LIfe Sciences 2032

The panel discussion was challenged by questions from the audience.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Michael Bonney presses the flesh.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston LIfe Sciences 2032

Xconomy Xchange: Boston LIfe Sciences 2032

Dennis Ausiello does some pre-panel networking.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Millennium's Paul Kidwell and his staff made sure everything ran smoothly.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Networking at the post-panel reception.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

Food, drinks, and some sweet decor from our hosts, Millennium: The Takeda Oncology Company.

Photo by Keith Spiro Photography courtesy of Kendall Press

Xconomy Xchange: Boston Life Sciences 2032

Xconomy Xchange: Boston Life Sciences 2032

The Boston Life Sciences 2032 crowd seemed to enjoy themselves. So did we.

Photo by Keith Spiro Photography courtesy of Kendall Press

Four and a half years ago, we organized a special Xconomy biotech forum: an evening focused on what the Boston life sciences scene would look like 20 years down the road. Fast forward through a major recession, a new presidency, and further increases in healthcare costs, and the life sciences world looks much different already. So we thought it was high time to bring together some of the biggest names in the Boston biotech scene (and beyond) to discuss and revisit the changes we might expect to see in the next 20 years.

Our speakers, whom you can learn more about in this slideshow, were Deborah Dunsire, John Mendlein, Michael Bonney, Noubar Afeyan, and Dennis Ausiello. Their discussion topics included the increasing importance of big data and mobile health, the necessity of finding ways to lower the costs of developing and administering treatments, and the vitality of startups within the life sciences ecosystem.

A huge thanks to Millennium: The Takeda Oncology Company for being outstanding event hosts. A special thanks also to our event sponsors: BDO, Cubist Pharmaceuticals, Halloran Consulting Group, and Perkins + Will, as well as to our event partner, MassBio. And of course, huge thanks to KeithSpiroPhoto courtesy of Kendall PRess for the pictures. Enjoy.

Thea Bissell did the actual work of assembling this slideshow.

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com or call him at 617-252-7323.